An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

Pediatric Pulmonology

Volumn 45, Issue 11, 2010, Pages 1121-1134

  Oermann, Christopher M ^a   Retsch bogart, George Z ^b   Quittner, Alexandra L ^c   Gibson, Ronald L ^d   Mccoy, Karen S ^e   Montgomery, A Bruce ^f   Cooper, Peter J ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f GILEAD SCIENCES INC   (United States)

Author keywords

antibiotic; Pseudomonas aeruginosa; pulmonary function; quality of life

Indexed keywords

AZITHROMYCIN; AZTREONAM; BRONCHODILATING AGENT; CAYSTON; CEFOXITIN; DORNASE ALFA; FLUTICASONE PROPIONATE PLUS SALMETEROL; PANCREAS ENZYME; SALBUTAMOL; TOBRAMYCIN; UNCLASSIFIED DRUG; VITAMIN;

ACHROMOBACTER XYLOSOXIDANS; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APPETITE; ARTICLE; ASPERGILLUS; BLOOD PRESSURE; BREATHING RATE; BURKHOLDERIA; CANDIDA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NOSE CONGESTION; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RHINORRHEA; SCHOOL CHILD; SIDE EFFECT; SINUS CONGESTION; SORE THROAT; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; SYMPTOM; THORAX PAIN; WEIGHT GAIN; WHEEZING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZTREONAM; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449294500     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21301     Document Type: Article

References (30)

1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B,. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957 - 969.
2. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL,. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41: 656 - 665.
3. Bristol-Myers Squibb, Bristol-Myers Squibb. AZACTAM (aztreonam for injection) [package insert]. 2007.
4. Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P,. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975; 55: 96 - 100.
5. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB,. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921 - 928.
6. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ,. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135: 1223 - 1232.
7. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL,. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23 - 30.
8. Bucholski A, Keller M, Balcke A, Lintz FC, Seemann S, Flitter WD, Hofmann T,. In vitro Performance of eFlow, an electronic inhaler for administration of a novel aztreonam formulation to CF patients [abstract 396]. Pediatr Pulmonol Suppl 2003; 25: 321.
9. American Thoracic Society Committee on Diagnostic Standards for Non-Tuberculous Respiratory Diseases. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152: 1107 - 1136.
10. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B,. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725 - 734.
11. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB,. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135: 1610 - 1618.
12. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd, Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4 - S14.
13. Guyatt GH,. Making sense of quality-of-life data. Med Care 2000; II175 - II179.
14. Jaeschke R, Singer J, Guyatt GH,. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407 - 415.
15. Burns JL, Emerson J, McNamara S, Worrell K, Buccat A,. Antibiotic resistance in cystic fibrosis sputum isolates [abstract 373]. Pediatr Pulmonol 2008; 43: 334.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18. Wayne (PA): CLSI (formerly NCCLS); 2008.
17. Quittner A, Modi A, Wainwright C, Otto K, Kirihara J, Montgomery AB,. Determination of the minimal clinically important difference (MCID) scores for the Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptom scale in two populations of patients with CF and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135: 1610 - 1618.
18. Pathogenesis Corporation. Technical Monograph TOBI Tobramycin Solution for Inhalation, International Edition. Seattle: The Corporation; 2000.
19. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084 - 1089.
20. Boyle MP,. Adult cystic fibrosis. JAMA 2007; 298: 1787 - 1793.
21. Gozdzik J, Cofta S, Piorunek T, Batura-Gabryel H, Kosicki J,. Relationship between nutritional status and pulmonary function in adult cystic fibrosis patients. J Physiol Pharmacol 2008; 59: 253 - 260.
22. Montgomery AB, S. Lewis M, K. Higuchi M, Marshall B,., Oermann C,. Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF). Am J Respir Crit Care Med 2009; 179: A1188.
23. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report To The Center Directors 2006. Bethesda, Maryland, 2007.
24. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL,. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008; 43: 47 - 58.
25. Oie S, Fukui Y, Yamamoto M, Masuda Y, Kamiya A,. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa. BMC Infect Dis 2009; 9: 123 - 127.
26. Dong Y, Zhao X, Kreiswirth BN, Drlica K,. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2581 - 2584.
27. Ward H, Perron GG, Maclean RC,. The cost of multiple drug resistance in Pseudomonas aeruginosa. J Evol Biol 2009; 22: 997 - 1003.
28. Bakare N, Rickerts V, Bargon J, Just-Nübling G,. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46: 19 - 23.
29. Appel GB,. Aminoglycoside nephrotoxicity. Am J Med 1990; 16S - 20S; discussion 38S-42S.
30. Myhre JL, DePaoli A, Keim GR,. Ototoxicity of subcutaneously administered aztreonam in neonatal rats. Toxicol Appl Pharmacol 1985; 77: 108 - 115.